NCT04269057 is a clinical trial in Heart Failure, sponsored by Chongqing Medical University.

Who is sponsoring NCT04269057?

NCT04269057 is sponsored by Chongqing Medical University.

What condition does NCT04269057 study?

NCT04269057 studies Heart Failure.

Is NCT04269057 still recruiting?

NCT04269057 is currently status unknown. Last updated 17 February 2020.

Last reviewed 2020-02-17 · How we verify

NCT04269057

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI

Status unknown Last updated 17 February 2020

What this trial tests

trial in Heart Failure in 90 participants. Status unknown.

Timeline

1 October 2019

Primary endpoint
1 October 2020

1 October 2020

Quick facts

Lead sponsor	Chongqing Medical University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	90
Start date	1 October 2019
Primary completion	1 October 2020
Estimated completion	1 October 2020
Sites	1 location across China

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Chongqing Medical University

Who can join

Eligibility, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Underlying inflammation has been increasingly recognized in heart failure with a preserved ejection fraction(HFpEF). But there is no study reported the relationship between NLRP3 inflammasome and HFpEF. In this study, investigators propose a scientific hypothesis that the expression of NLRP3 inflammasome is elevated in patients with HFpEF, and the level of TNFα, IL-1β and NLRP3 inflammasome is lower in patients treated with sacubitril/valsartan.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Chronic low-grade inflammation in heart failure with preserved ejection fraction.
Mesquita T, Lin YN, Ibrahim A. · · 2021 · cited 77× · PMID 34382743 · DOI 10.1111/acel.13453
NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.
Ramachandran R, Manan A, Kim J, Choi S. · · 2024 · cited 67× · PMID 38945951 · DOI 10.1038/s12276-024-01261-8
Inflammatory Pathways and Their Implications in Heart Failure With Preserved Ejection Fraction.
Segar MW, Coulter SA. · · 2023 · cited 1× · PMID 37867309 · DOI 10.14503/thij-23-8223

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Chongqing Medical University trials

Trials by the same sponsor.

NCT07298889 — High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS · NA · recruiting
NCT07503509 — Physiological Study of High PEEP in Noninvasive Ventilation · NA · recruiting
NCT06118671 — The Evaluation of Artificial Intelligence in Lifestyle Management of Diabetic Patients in Community · NA · unknown
NCT06272032 — Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis · EARLY_PHASE1 · unknown
NCT05974566 — Efficacy and Safety of Finerenone in Heart Failure With Reduced Ejection Fraction · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04269057 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chongqing Medical University
Last refreshed: 17 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04269057.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing